Does Retatrutide Lower Blood Pressure? What Phase 2 Actually Showed

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited

Investigational drug notice

Retatrutide is an investigational drug. It has not been approved by the FDA and is not available outside clinical trials. FormBlends does not sell, supply, prescribe, or facilitate access to retatrutide. The blood pressure data on this page comes from the published phase 2 trial and the broader GLP-1 class literature. Clinical management of hypertension while on weight-loss medications should be directed by the prescribing clinician.

Key Takeaways

• Phase 2 retatrutide reduced mean systolic blood pressure by approximately 7-8 mmHg at top doses over 48 weeks
• Diastolic blood pressure dropped by approximately 2-4 mmHg
• Placebo arm BP changes were minimal, so the active-versus-placebo gap is real and meaningful
• The effect tracks with weight loss, suggesting most of the benefit is downstream of weight reduction rather than a direct vascular drug effect
• Patients on antihypertensive medications often need dose reductions as weight loss progresses to avoid excessive BP drops

Direct answer

Yes. Retatrutide lowers systolic and diastolic blood pressure, with reductions in the 7-8 mmHg systolic range at top doses. The magnitude is similar to semaglutide and tirzepatide in matched comparisons and is consistent with what 20-25% weight loss typically produces. For patients with obesity-related hypertension, retatrutide would be expected to produce clinically meaningful BP improvement. For patients without hypertension, BP usually drops slightly into a still-normal range.

Table of contents

1. The phase 2 blood pressure data in detail
2. How BP responds to weight loss generally
3. Mechanisms beyond weight loss
4. Comparison across the GLP-1 class
5. What happens to antihypertensive medications during weight loss
6. Orthostatic considerations
7. The patient who improves dramatically vs the patient who does not
8. When to monitor and how
9. Cardiovascular outcome implications
10. The contrary view: weight loss is not always durable
11. FAQ
12. Sources

The phase 2 blood pressure data in detail

The Jastreboff et al. NEJM 2023 paper reports blood pressure as a secondary endpoint. Mean changes from baseline at week 48:

Arm	Systolic BP change	Diastolic BP change
Placebo	-0.9 mmHg	-0.4 mmHg
1 mg retatrutide	-2.5 mmHg	-1.2 mmHg
4 mg retatrutide	-4.6 mmHg	-2.1 mmHg
8 mg retatrutide	-7.2 mmHg	-3.1 mmHg
12 mg retatrutide	-7.5 mmHg	-3.5 mmHg

The drug-versus-placebo gap at 12 mg is approximately 6.6 mmHg systolic and 3.1 mmHg diastolic. The dose-response is steep at lower doses and plateaus between 8 mg and 12 mg, matching the weight-loss dose-response curve. This is consistent with weight-loss-mediated mechanisms accounting for most of the effect.

How BP responds to weight loss generally

Weight loss is one of the most consistent non-pharmacologic interventions for hypertension. The mechanisms are well established:

• Reduced cardiac output. Less adipose tissue means less circulating volume that the heart must pump, which lowers cardiac output and downstream pressure
• Lower sympathetic tone. Obesity is associated with chronically elevated sympathetic nervous system activity. Weight loss reduces this
• Better renal sodium handling. Obesity impairs sodium excretion through multiple mechanisms (RAAS activation, leptin effects, inflammatory signaling). Weight loss improves natriuresis
• Reduced inflammation. Obesity is a chronic inflammatory state. Adipokines and inflammatory cytokines contribute to vascular dysfunction. Weight loss reduces this load
• Improved vascular function. Endothelial function improves with weight loss, allowing better vasodilation in response to physiologic demand

The expected magnitude of BP improvement with weight loss is approximately 1 mmHg systolic per kilogram lost in the early phase, with smaller gains as weight loss progresses. A patient losing 20-25% of body weight (typically 20-30 kg) would expect 10-20 mmHg systolic improvement based on this rule of thumb. The retatrutide phase 2 mean of ~7.5 mmHg is on the lower end of that range, possibly because the cohort included many patients with normal or near-normal baseline BP who had less room for improvement.

Mechanisms beyond weight loss

Whether retatrutide has direct vascular effects independent of weight loss is not definitively answered by phase 2 data. Several mechanistic possibilities exist:

• Natriuresis. GLP-1 receptor agonism has been shown to increase renal sodium excretion in some studies, independent of weight
• Endothelial function. GLP-1 receptor agonists may directly improve endothelial nitric oxide production. Animal studies support this; human data is mixed
• Sympathetic modulation. Incretin signaling may directly affect autonomic balance
• Glucagon receptor effects. Glucagon receptor activation has mixed cardiovascular effects, including some vasodilatory effects through cAMP signaling, balanced against the small heart rate increase

The BP effects of retatrutide may include a small contribution from these direct mechanisms on top of the larger weight-loss-mediated effect. Disentangling them requires controlled studies that have not been published.

Comparison across the GLP-1 class

Drug	Trial	Systolic BP reduction at top dose
Liraglutide 3.0 mg	SCALE Obesity	~3-4 mmHg
Semaglutide 2.4 mg	STEP 1	~6 mmHg
Tirzepatide 15 mg	SURMOUNT-1	~7 mmHg
Retatrutide 12 mg	Phase 2	~7.5 mmHg

The BP effect roughly tracks weight loss magnitude across the class, supporting the weight-mediated hypothesis. Retatrutide's slightly larger BP reduction matches its slightly larger weight reduction.

What happens to antihypertensive medications during weight loss

Patients on baseline antihypertensives commonly experience clinically meaningful BP improvement as weight loss progresses. Three patterns are seen:

Pattern 1: Medications stay the same, BP drops into ideal range. Common for patients with mild hypertension on monotherapy. BP moves from 140/85 to 120/75 over the first 6-12 months. No medication change needed.

Pattern 2: Medications need reduction. Common for patients on multi-drug regimens or with significant baseline weight loss. BP drops faster than weight loss alone would predict, sometimes to 100/60 or lower, with orthostatic symptoms. Clinicians reduce doses or eliminate medications as needed.

Pattern 3: Medications can be discontinued entirely. Some patients achieve normotension off all medications after significant weight loss. The pattern is most common in patients whose hypertension was clearly obesity-driven (relatively short duration, no major end-organ damage).

The clinical principle is to titrate antihypertensives downward as weight loss progresses, not to discontinue abruptly. Home BP monitoring is essential. Patients should not stop antihypertensive medications without clinical input.

Orthostatic considerations

Orthostatic hypotension (a drop of 20 mmHg systolic or 10 mmHg diastolic on standing) can develop during early treatment for several reasons:

• Reduced fluid intake from nausea
• Reduced sodium intake from decreased eating
• Continued full-dose antihypertensive medications as BP drops
• Volume contraction from weight loss

Patients should be counseled to rise slowly, maintain hydration, and contact their clinician if they experience dizziness on standing. Adjusting antihypertensive doses early often prevents this issue. Adding salt to meals or temporarily increasing fluid intake can also help during the titration window.

The patient who improves dramatically vs the patient who does not

Not every hypertensive patient experiences dramatic BP improvement with weight loss. Factors that predict large BP drops:

• Higher baseline BP
• Shorter duration of hypertension
• Younger age
• Absence of significant left ventricular hypertrophy or other end-organ remodeling
• Larger absolute weight loss
• Larger reductions in visceral adiposity specifically

Patients with long-standing hypertension that has produced vascular remodeling (arterial stiffening, LVH) may see smaller BP improvements despite significant weight loss. The vascular changes from years of high pressure are not fully reversible.

This does not mean weight loss is not worth doing in long-standing hypertension. Even modest BP improvements add to cardiovascular benefit. But realistic expectations should match the patient's baseline situation.

When to monitor and how

For patients on FDA-approved GLP-1 drugs, reasonable monitoring approach:

• Document baseline BP before starting
• Home BP monitor for patients with baseline hypertension or on antihypertensives. Twice-weekly to daily measurements during titration
• Clinic visits every 4-8 weeks during titration for patients on multiple antihypertensives
• Less intensive monitoring once weight loss has stabilized and antihypertensive regimen has been adjusted
• Re-evaluation if symptoms emerge (lightheadedness, fatigue out of proportion to weight loss, syncope)

Patients without hypertension and not on antihypertensive medications generally do not need intensive BP monitoring. Routine BP checks at follow-up visits are usually sufficient.

Cardiovascular outcome implications

The BP reduction is part of the overall cardiovascular benefit of the GLP-1 class. The SELECT trial (Lincoff et al., NEJM 2023) showed semaglutide reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease and obesity. Some of that benefit is attributable to BP reduction, some to weight loss generally, some to direct cardiac effects, and some to glycemic improvement.

For retatrutide, cardiovascular outcome data is not yet available. The expected outcome based on shared mechanism class is favorable, but unproven. Phase 3 trials and post-approval studies will eventually characterize the cardiovascular profile in detail.

The contrary view: weight loss is not always durable

The BP improvements described above assume sustained weight loss. The harder clinical question is whether weight loss persists when patients discontinue the drug. Most data suggests it does not. The STEP 5 trial showed that semaglutide patients regained much of their weight loss after stopping. The SURMOUNT-4 maintenance trial showed similar patterns for tirzepatide. When weight returns, BP usually returns to pretreatment levels as well.

The clinical implication for hypertension management: GLP-1 class drugs work for BP only while the patient is taking them. Discontinuation tends to undo most of the gains over 1-2 years. Patients should be counseled that hypertension management with these drugs is ongoing, not a one-time treatment.

This has policy implications. If insurance coverage for obesity pharmacotherapy is time-limited (some plans cover only 1-2 years), the BP benefits will likely fade once coverage ends. For patients with hypertension as a driving comorbidity, long-term coverage decisions are clinically important.

For patients who anticipate stopping treatment, lifestyle changes during the medicated weight-loss period (diet quality improvements, regular exercise habits, sleep hygiene) may help preserve some of the BP benefit even if weight rebounds partially.

FAQ

Does retatrutide replace blood pressure medication? Not as a planned strategy. It can reduce the need for BP medications in some patients, but the goal is weight management with BP improvement as a downstream benefit, not BP control as the primary use.

How fast does the BP effect happen? Within the first 4-8 weeks for most patients, with continued slow improvement through the titration and maintenance period.

Can low blood pressure on retatrutide be dangerous? Symptomatic hypotension can be. Asymptomatic BP in the 100/60 range is generally well tolerated in healthy adults but requires attention in elderly patients or those with vascular disease.

Do I need to reduce my BP medications before starting? Not necessarily. Clinicians typically watch and adjust as weight loss progresses rather than reducing preemptively. Patients on multiple antihypertensives or with borderline baseline BP may have proactive adjustments.

Is the BP effect bigger in patients with higher baseline BP? Yes, typically. Patients with stage 1 or stage 2 hypertension see larger absolute BP reductions than normotensive patients.

Will my BP go back up if I stop the drug? Usually yes, in parallel with weight regain. Sustained lifestyle changes can partially offset this.

Does this affect heart failure? The BP and weight effects of GLP-1 drugs may benefit heart failure with preserved ejection fraction. The STEP-HFpEF trial of semaglutide showed improvements in HFpEF symptoms. Retatrutide-specific HFpEF data is not yet available.

Should I take my blood pressure at the same time every day? Consistent timing (typically morning before medications) gives the most interpretable trend. Mix of morning and evening readings is also useful for capturing variability.

Sources

1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. New England Journal of Medicine. 2023;389:514-526.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384:989-1002.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022.
4. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM. 2023.
5. Kosiborod MN et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF). NEJM. 2023.
6. Rosenstock J et al. Retatrutide in Type 2 Diabetes: A Phase 2 Trial. The Lancet. 2023.
7. Pi-Sunyer X et al. SCALE Obesity Trial. NEJM. 2015.
8. Whelton PK et al. ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018.
9. Wadden TA et al. Tirzepatide After Intensive Lifestyle Intervention in Adults with Overweight or Obesity (SURMOUNT-3). Nature Medicine. 2023.
10. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024.
11. Endocrine Society Clinical Practice Guideline on Pharmacological Management of Obesity, 2024 Update.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital telehealth platform that connects patients with independent licensed providers and U.S.-based pharmacies. Treatment decisions, including blood pressure management and antihypertensive medication adjustments during weight loss, are clinical decisions made by the prescribing provider.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are produced by state-licensed 503A compounding pharmacies in response to individual prescriptions. They are not FDA-approved and are not interchangeable with branded products. Blood pressure effects of compounded products are presumed similar to branded equivalents.

Investigational Drug Notice. Retatrutide is investigational and not FDA-approved. FormBlends does not sell, supply, or facilitate access to retatrutide. Blood pressure data on this page is from the published phase 2 trial.

Results Disclaimer. Blood pressure reductions reported in clinical trials reflect mean responses in study populations. Individual responses vary based on baseline BP, duration of hypertension, antihypertensive regimen, and individual physiology.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Saxenda is a registered trademark of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.